---
title: "Alvotech (ALVO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ALVO.US.md"
symbol: "ALVO.US"
name: "Alvotech"
industry: "生物技术"
---

# Alvotech (ALVO.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.alvotech.com](https://www.alvotech.com) |

## Company Profile

Alvotech 通过其子公司开发和制造生物仿制药，以服务全球患者。它在自身免疫、眼部和骨骼疾病以及癌症等治疗领域提供生物仿制药产品。该公司的主要项目是 AVT02，这是一种高浓度配方的生物仿制药，仿制 Humira，用于治疗各种炎症性疾病，包括类风湿关节炎、银屑病关节炎、克罗恩病、溃疡性结肠炎、斑块状银屑病及其他适应症；AVT04，仿制 Stelara，用于治疗包括银屑病关节炎、克罗恩病、溃疡性结肠炎、斑块状银屑病及其他适应症在内的各种炎症性疾病；AVT06，仿制 Eylea，用于治疗多种疾病，如年龄相关性黄斑变性、黄斑水肿和糖尿病视网膜病变；以及 AVT03，仿制 Xgeva 和 Prol...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:12.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 100 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.55% |  |
| Net Profit YoY | 115.74% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -8.22 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.45B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 573.35M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -26.71% | E |
| Profit Margin | 12.12% | B |
| Gross Margin | 69.26% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.55% | A |
| Net Profit YoY | 115.74% | A |
| Total Assets YoY | 14.29% | B |
| Net Assets YoY | 48.57% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 824.98% | B |
| OCF YoY | 45.55% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.43 | C |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 112.54% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Alvotech",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-26.71%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "12.12%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "69.26%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "45.55%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "115.74%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.29%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "48.57%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "824.98%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "45.55%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "112.54%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 20.90 | 31/605 | 39.77 | 28.72 | 23.15 |
| PB | -8.22 | 532/605 | - | - | - |
| PS (TTM) | 2.53 | 61/605 | 5.28 | 4.64 | 2.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-17T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 50% |
| Overweight | 1 | 17% |
| Hold | 1 | 17% |
| Underweight | 1 | 17% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.64 |
| Highest Target | 90.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ALVO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ALVO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ALVO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.